AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that the US Food and Drug Administration approved Klygefa (gefurulimab) for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
Key Highlights
- FDA approval granted: Klygefa (gefurulimab) was approved in the US for adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
- Primary endpoint met: The PREVAIL Phase III trial showed a statistically significant improvement from baseline in MG-ADL total score at week 26 versus placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001), according to the filing.
- Rapid onset observed: Clinical improvement was observed as early as week one, with the filing noting improvements were sustained through one year.
- First-of-its-kind designation: According to the filing, Klygefa is described as the first and only approved dual-binding nanobody C5 inhibitor in the US, with once-weekly subcutaneous self-administration via autoinjector.
- Safety profile: The most common treatment-emergent adverse events in patients receiving Klygefa were injection site reactions (12%), back pain (8%), and vomiting (5%), the filing disclosed.
- US patient population: The filing states an estimated 98,500 people in the US are diagnosed with gMG, with 81,000 being AChR-positive.
- Existing approvals: The filing notes Klygefa is already approved in the European Union, Japan, and other countries for certain adults with gMG.
AstraZeneca Discloses US FDA Approval of Gefurulimab for gMG
AstraZeneca PLC (NYSE:AZN) reported, via a Form 6-K covering the month of November 2026, that its Alexion unit received FDA approval for Klygefa (gefurulimab) for adult gMG patients who are AChR antibody positive. According to the filing, gMG is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness, with approximately 85% of people with gMG being AChR antibody-positive.
The approval was based on results from the PREVAIL (ALXN1720-MG-301) Phase III trial, described in the filing as a global, randomised, double-blind, placebo-controlled, multicentre study that enrolled 260 patients from 20 countries. Patients were randomised 1:1 to receive Klygefa or placebo for 26 weeks, with a single weight-based loading dose on Day 1 followed by once-weekly weight-based maintenance dosing beginning on Day 8. The filing states that patients who completed the randomised controlled treatment period were eligible to continue into an ongoing open-label extension period.
The filing disclosed that Klygefa was generally well-tolerated and that the percentage of participants with treatment-emergent adverse events was similar between the Klygefa and placebo groups. Most treatment-emergent adverse events were mild to moderate in severity (grade 1 or 2). The filing also noted that the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG. Regulatory submissions based on PREVAIL results are described as under review in China and additional countries.
What Was Disclosed
AstraZeneca filed a Form 6-K disclosing FDA approval of Klygefa (gefurulimab) for AChR antibody-positive adult gMG patients, supported by statistically significant PREVAIL Phase III trial results, with once-weekly subcutaneous self-administration via autoinjector.




Please wait processing your request...